
    
      1. Dose-escalation:Patients entered the IM19-41BB or IM19-CD28 group and performed dose
           escalation studies in three dose groups.

        2. According to the results of the previous dose escalation study, select one dose to
           continue the enrollment of 6 patients for extended studies.
    
  